病毒样颗粒 (VLP) 疫苗在癌症免疫治疗中的应用。
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.
机构信息
Department of Medical and Surgical Sciences (DIMEC) and Alma Mater Institute on Healthy Planet, University of Bologna, 40126 Bologna, Italy.
Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
出版信息
Int J Mol Sci. 2023 Aug 19;24(16):12963. doi: 10.3390/ijms241612963.
Abstract
Cancer vaccines are increasingly being studied as a possible strategy to prevent and treat cancers. While several prophylactic vaccines for virus-caused cancers are approved and efficiently used worldwide, the development of therapeutic cancer vaccines needs to be further implemented. Virus-like particles (VLPs) are self-assembled protein structures that mimic native viruses or bacteriophages but lack the replicative material. VLP platforms are designed to display single or multiple antigens with a high-density pattern, which can trigger both cellular and humoral responses. The aim of this review is to provide a comprehensive overview of preventive VLP-based vaccines currently approved worldwide against HBV and HPV infections or under evaluation to prevent virus-caused cancers. Furthermore, preclinical and early clinical data on prophylactic and therapeutic VLP-based cancer vaccines were summarized with a focus on HER-2-positive breast cancer.
摘要
癌症疫苗作为预防和治疗癌症的一种可能策略，越来越受到关注。虽然已经批准并在全球范围内有效使用了几种针对病毒引起的癌症的预防性疫苗，但治疗性癌症疫苗的开发仍需要进一步实施。病毒样颗粒（VLPs）是自我组装的蛋白质结构，模拟天然病毒或噬菌体，但缺乏复制材料。VLP 平台旨在以高密度模式展示单个或多个抗原，从而引发细胞和体液反应。本综述的目的是全面概述目前全球批准用于预防 HBV 和 HPV 感染或正在评估以预防病毒引起的癌症的预防性基于 VLP 的疫苗。此外，还总结了预防性和治疗性基于 VLP 的癌症疫苗的临床前和早期临床数据，重点是 HER-2 阳性乳腺癌。
相似文献
1
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.病毒样颗粒 (VLP) 疫苗在癌症免疫治疗中的应用。
Int J Mol Sci. 2023 Aug 19;24(16):12963. doi: 10.3390/ijms241612963.
2
P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy.P22 病毒样颗粒作为一种有效的抗原传递纳米平台用于癌症免疫治疗。
Biomaterials. 2021 Apr;271:120726. doi: 10.1016/j.biomaterials.2021.120726. Epub 2021 Feb 18.
3
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines.病毒样颗粒作为癌症预防和治疗性疫苗
Vaccines (Basel). 2022 Feb 2;10(2):227. doi: 10.3390/vaccines10020227.
4
Bacterial superglue enables easy development of efficient virus-like particle based vaccines.细菌胶水助力高效病毒样颗粒疫苗的轻松研发。
J Nanobiotechnology. 2016 Apr 27;14:30. doi: 10.1186/s12951-016-0181-1.
5
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.由L1/L2嵌合病毒样颗粒组成的人乳头瘤病毒疫苗在临床前模型中诱导产生广泛的交叉保护作用。
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
6
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?基于病毒样颗粒的抗人乳头瘤病毒疫苗：我们如今进展如何？
Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018.
7
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.重组改良安卡拉痘苗病毒产生埃博拉病毒样颗粒。
J Virol. 2017 May 12;91(11). doi: 10.1128/JVI.00343-17. Print 2017 Jun 1.
8
Virus-like particles for the prevention of human papillomavirus-associated malignancies.病毒样颗粒用于预防人乳头瘤病毒相关性恶性肿瘤。
Expert Rev Vaccines. 2013 Feb;12(2):129-41. doi: 10.1586/erv.12.151.
9
10
Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.基于嵌合病毒样颗粒的人乳头瘤病毒和 HIV 疫苗设计：经验教训。
AIDS Rev. 2019;21(4):218-232. doi: 10.24875/AIDSRev.19000114.
引用本文的文献
1
Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.癌症治疗中的仿生纳米疫苗：作用机制、疗效及临床转化
Mater Today Bio. 2025 Jul 18;34:102116. doi: 10.1016/j.mtbio.2025.102116. eCollection 2025 Oct.
2
Strategic Advances in Targeted Delivery Carriers for Therapeutic Cancer Vaccines.治疗性癌症疫苗靶向递送载体的战略进展
Int J Mol Sci. 2025 Jul 17;26(14):6879. doi: 10.3390/ijms26146879.
3
A Milestone in the Shift from "Passive Killing" to "Active Immunomodulation" in Cancer Treatment-Progress in Melanoma Vaccine Research.癌症治疗从“被动杀伤”到“主动免疫调节”转变中的一个里程碑——黑色素瘤疫苗研究进展
Curr Treat Options Oncol. 2025 Jul 17. doi: 10.1007/s11864-025-01340-6.
4
The Bioengineering of Insect Cell Lines for Biotherapeutics and Vaccine Production: An Updated Review.用于生物治疗和疫苗生产的昆虫细胞系生物工程：最新综述
Vaccines (Basel). 2025 May 23;13(6):556. doi: 10.3390/vaccines13060556.
5
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape.核酸递送的纳米方法：障碍、解决方案及当前态势
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Mar-Apr;17(2):e70010. doi: 10.1002/wnan.70010.
6
Development of a blocking ELISA employing a VP1-specific monoclonal antibody for the detection of DHAV3 antibodies.利用VP1特异性单克隆抗体开发用于检测鸭甲型肝炎病毒3型抗体的阻断酶联免疫吸附测定法。
Poult Sci. 2025 Apr 5;104(6):105080. doi: 10.1016/j.psj.2025.105080.
7
The Use of Plant Viral Nanoparticles in Cancer Biotherapy-A Review.植物病毒纳米颗粒在癌症生物治疗中的应用——综述
Viruses. 2025 Feb 1;17(2):218. doi: 10.3390/v17020218.
8
The Role of Plant Virus-like Particles in Advanced Drug Delivery and Vaccine Development: Structural Attributes and Application Potential.植物病毒样颗粒在先进药物递送和疫苗开发中的作用：结构特性与应用潜力
Viruses. 2025 Jan 23;17(2):148. doi: 10.3390/v17020148.
9
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.通过一种基于创新型cVLP的疫苗靶向前蛋白转化酶枯草溶菌素9（PCSK9），增强了cVLP-人表皮生长因子受体2（HER2）疫苗在HER2阳性乳腺癌临床前模型中的治疗活性。
J Transl Med. 2025 Jan 30;23(1):136. doi: 10.1186/s12967-025-06126-w.
10
Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.肿瘤微环境重塑：克服三阴性乳腺癌治疗耐药性及创新免疫工程的策略
Front Immunol. 2024 Dec 10;15:1455211. doi: 10.3389/fimmu.2024.1455211. eCollection 2024.
本文引用的文献
1
Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapy.免疫抑制药物治疗个体中接种 HepB-CpG 疫苗。
Vaccine. 2023 Jul 12;41(31):4457-4461. doi: 10.1016/j.vaccine.2023.06.041. Epub 2023 Jun 21.
2
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.个体化 RNA 新抗原疫苗可刺激胰腺癌中的 T 细胞。
Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10.
3
Assessing the Efficacy of VLP-Based Vaccine against Epstein-Barr Virus Using a Rabbit Model.使用兔模型评估基于病毒样颗粒的疫苗对 Epstein-Barr 病毒的疗效。
Vaccines (Basel). 2023 Feb 24;11(3):540. doi: 10.3390/vaccines11030540.
4
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer.使用 Toll 样受体激动剂降低癌症负担的应用及临床试验概况
NPJ Precis Oncol. 2023 Mar 8;7(1):26. doi: 10.1038/s41698-023-00364-1.
5
Neoadjuvant treatment for stage III and IV cutaneous melanoma.新辅助治疗 III 期和 IV 期皮肤黑色素瘤。
Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2.
6
Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth.携带肿瘤抗原的腺病毒启发的病毒样颗粒对免疫系统的刺激可控制黑色素瘤的生长。
Mol Ther Methods Clin Dev. 2022 Dec 7;28:76-89. doi: 10.1016/j.omtm.2022.12.003. eCollection 2023 Mar 9.
7
Neoantigens: promising targets for cancer therapy.肿瘤新抗原：癌症治疗的有前途的靶点。
Signal Transduct Target Ther. 2023 Jan 6;8(1):9. doi: 10.1038/s41392-022-01270-x.
8
Hepatitis B Therapeutic Vaccine: A Patent Review.乙肝治疗性疫苗：专利综述
Pharmaceuticals (Basel). 2022 Dec 12;15(12):1542. doi: 10.3390/ph15121542.
9
ADK-VR2, a cell line derived from a treatment-naïve patient with fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.ADK-VR2，一种源自未经治疗的原发性克唑替尼耐药的融合阳性非小细胞肺癌患者的细胞系：一种用于ROS1重排非小细胞肺癌新药开发的新型临床前模型。
Transl Lung Cancer Res. 2022 Nov;11(11):2216-2229. doi: 10.21037/tlcr-22-163.
10
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.一项在晚期实体瘤患者中开展的抗 OX40 激动剂 INCAGN01949 的首次人体 I/II 期、开放性研究。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2021-004235.
Zotero 插件